title: Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient.
abstract: We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
authors.affiliation: Hematology-Oncology Department, Faculty of Medicine, Saint-Joseph University , Beirut , Lebanon .
authors.forename: Marwan
authors.initials: M
authors.lastname: Ghosn
authors.affiliation: Hematology-Oncology Department, Faculty of Medicine, Saint-Joseph University , Beirut , Lebanon .
authors.forename: Alain
authors.initials: A
authors.lastname: Dagher
authors.affiliation: Hematology-Oncology Department, Faculty of Medicine, Saint-Joseph University , Beirut , Lebanon .
authors.forename: Fadi
authors.initials: F
authors.lastname: El-Karak
keywords: cabazitaxel; docetaxel; doubling time; prostate cancer; prostate-specific antigen